Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Dalvabancin – Second-Generation Glycopeptide for Serious Gram-Positive Infections

Drug (Brand / Generic)

Dalbavancin

Company / Licensee

Durata Therapeutics

Therapy Class

Glycopeptide

Product Description

Antibiotic

Current Indication

Treatment of complicated skin and soft tissue infections due to Gram-positive pathogens

Market Sector

Anti-infectives

Development Status

Phase III
Expand
Close
Close
Close

Go Top